Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products

Journal of Thrombosis and Thrombolysis - In the original publication of the article, unfortunately the given name and family name of the author’s in the author group were inadvertently...     

“三级靶向”理论破解“上火”之谜

人为什么会“上火”？为什么有时人们治疗“上火”效果不佳？近日，由广州白云山和记黄埔中药有限公司现代中药研究院与广州中医药大学“中药抗生素”联合实验室共同开展的中医治疗“上火”课题研究取得了进展——提出“三级靶向”理论，破解人体“上火”之谜。     

美容趋势新破解

变漂亮就像一场美丽的战争。过去想变脸，势必得经过一场“腥风血雨”，但现在的美容医学已经升华到不必刀光剑影，也没有见血的惊悚画面，在赐予青春美貌的同时，还省下了让人担惊受怕的种种。这里请来二位知足皮肤科专家，为我们现身说明你可能透过整型达到美丽肌肤未来。[编者按]     

原位肝移植术后病人的早期监护

目的总结肝移植术后病人在ICU监护期间的护理经验。方法通过对3例肝移植术后病人在ICU期间的生命体征、排斥反应、预防感染等的监测,总结肝移植术后的护理重点及方法。结果3例患者中2例治愈出院,1例正接受康复治疗。住院期间1例发生肺部感染,其余未出现并发症。结论细致的早期监测与护理,可减少术后并发症,提高肝移植成功率。     

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products

To analyze the efficacy and safety of activated prothrombin complex concentrates (aPCC) and four-factor prothrombin complex concentrates (4F-PCC) to prevent hematoma expansion in patients taking apixaban or rivaroxaban with intracranial hemorrhage (ICH). In this multicenter, retrospective study, sixty-seven ICH patients who received aPCC or 4F-PCC for known use of apixaban or rivaroxaban between February 2014 and September 2018 were included. The primary outcome was the percentage of patients who achieved excellent/good or poor hemostasis after administration of aPCC or 4F-PCC. Secondary outcomes included hospital mortality, thromboembolic events during admission, and transfusion requirements. Excellent/good hemostasis was achieved in 87% of aPCC patients, 89% of low-dose 4F-PCC [<?30 units per kilogram (kg)], and 89% of high-dose 4F-PCC (≥?30 units per kg). There were no significant differences in excellent/good or poor hemostatic efficacy (p?=?0.362). No differences were identified in transfusions 6 h prior (p?=?0.087) or 12 h after (p?=?0.178) the reversal agent. Mortality occurred in five patients, with no differences among the groups (p?=?0.838). There were no inpatient thromboembolic events. Both aPCC and 4F-PCC appear safe and equally associated with hematoma stability in patients taking apixaban or rivaroxaban who present with ICH. Prospective studies are needed to identify a superior reversal agent when comparing andexanet alfa to hospital standard of care (4F-PCC or aPCC) and to further explore the optimal dosing strategy for patients with ICH associated with apixaban or rivaroxaban use.

     

炎夏一周变身黄金女郎

若担心太阳过于热烈会把皮肤晒得焦黑，热度会融化脸上美美的妆，那么我们在这里要告诉你如何利用一周七天，从头到脚彻底改造，让你在炎炎夏日中成为比阳光耀眼的黄金女郎！[编者按]